San Diego, CA, June 1, 2015 — Poseida Therapeutics, Inc. (“Poseida”), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (“Transposagen”), announces that company executives are scheduled to participate in the upcoming Jefferies 2015 Healthcare Conference in New York. The Company’s presentation will be on Monday, June 1 at 3:00 pm Eastern time. Eric Ostertag, M.D. Ph.D., Poseida’s CEO, will present for Poseida.

About Poseida Therapeutics

Poseida is a therapeutics-focused biotechnology company using best-in-class gene editing technologies to develop novel, life-saving therapies, including gene therapy for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida owns several industry-leading gene editing technologies, including the piggyBacTM DNA Modification System, XTNTM TALEN and NextGENTM CRISPR site-specific nucleases, and Footprint-FreeTM Gene Editing (FFGE). FFGE is the cleanest gene editing technology that is commercially available, allowing for surgically-precise changes of as little as a single nucleotide in any genome without unwanted mutations and with the ability to select for otherwise rare events.